The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk
Open accessAbstract
BACKGROUND: The appropriate duration of dual antiplatelet therapy in patients at high risk for bleeding after the implantation of a drug-eluting coronary stent remains unclear. METHODS: One month after they had undergone implantation of a biodegradable-polymer sirolimus-eluting coronary stent, we randomly assigned patients at high bleeding risk to discontinue dual antiplatelet therapy immediately (abbreviated therapy) or to continue it for at least 2 additional months (standard therapy). The three ranked primary outcomes were net adverse clinical events (a composite of death from any cause, myocardial infarction, stroke, or major bleeding), major adverse cardiac or cerebral events (a composite of death from any cause, myocardial infarction, or stroke), and major or clinically relevant nonmajor bleeding; cumulative incidences were assessed at 335 days. The first two outcomes were assessed for noninferiority in the per-protocol population, and the third outcome for superiority in the intention-to-treat population. RESULTS: Among the 4434 patients in the per-protocol population, net adverse clinical events occurred in 165 patients (7.5%) in the abbreviated-therapy group and in 172 (7.7%) in the standard-therapy group (difference, -0.23 percentage points; 95% confidence interval [CI], -1.80 to 1.33; P<0.001 for noninferiority). A total of 133 patients (6.1%) in the abbreviated-therapy group and 132 patients (5.9%) in the standard-therapy group had a major adverse cardiac or cerebral event (difference, 0.11 percentage points; 95% CI, -1.29 to 1.51; P = 0.001 for noninferiority). Among the 4579 patients in the intention-to-treat population, major or clinically relevant nonmajor bleeding occurred in 148 patients (6.5%) in the abbreviated-therapy group and in 211 (9.4%) in the standard-therapy group (difference, -2.82 percentage points; 95% CI, -4.40 to -1.24; P<0.001 for superiority). CONCLUSIONS: One month of dual antiplatelet therapy was noninferior to the continuation of therapy for at least 2 additional months with regard to the occurrence of net adverse clinical events and major adverse cardiac or cerebral events; abbreviated therapy also resulted in a lower incidence of major or clinically relevant nonmajor bleeding. (Funded by Terumo; MASTER DAPT ClinicalTrials.gov number, NCT03023020.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P. E., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 9,971
Self-citationClinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationMehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.009449 · Cited by 4,476
Self-citationValgimigli, M., Bueno, H., Byrne, R. A., Collet, J.-P., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P., Mauri, L., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx419 · Cited by 2,987
Self-citationWatanabe, H., Domei, T., Morimoto, T., Natsuaki, M., Shiomi, H., Toyota, T., Ohya, M., Suwa, S., Takagi, K., Nanasato, M., et al. (2019) · JAMA · doi:10.1001/jama.2019.8145 · Cited by 857
Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk
Urban, P., Meredith, I. T., Abizaid, A., Pocock, S. J., Carrié, D., Naber, C., Lipiecki, J., Richardt, G., Iñiguez, A., Brunel, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503943 · Cited by 818
Self-citationVranckx, P., Valgimigli, M., Jüni, P., Hamm, C., Steg, P. G., Heg, D., van Es, G. A., McFadden, E. P., Onuma, Y., van Meijeren, C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31858-0 · Cited by 791
Self-citationFeres, F. (2013) · JAMA · doi:10.1001/jama.2013.282183 · Cited by 589
Fiedler, K. A., Maeng, M., Mehilli, J., Schulz-Schüpke, S., Byrne, R. A., Sibbing, D., Hoppmann, P., Schneider, S., Fusaro, M., Ott, I., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.050 · Cited by 443
Gargiulo, G., Goette, A., Tijssen, J., Eckardt, L., Lewalter, T., Vranckx, P., & Valgimigli, M. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz732 · Cited by 318
Self-citation
Cited by
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
Self-citation2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C., Andreotti, F., Koskinas, K. C., Rossello, X., Adamo, M., Ainslie, J., Banning, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 2,774
Self-citationHalvorsen, S., Mehilli, J., Cassese, S., Hall, T. S., Abdelhamid, M., Barbato, E., De Hert, S., de Laval, I., Geisler, T., Hinterbuchner, L., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac270 · Cited by 1,141
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001309 · Cited by 625
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · JACC · doi:10.1016/j.jacc.2024.11.009 · Cited by 552
Metadata
- Authors
- Valgimigli, M., Frigoli, E., Heg, D., Tijssen, J., Jüni, P., Vranckx, P., Ozaki, Y., Morice, M.-C., Chevalier, B., Onuma, Y., Windecker, S., Tonino, P. A. L., Roffi, M., Lesiak, M., Mahfoud, F., Bartunek, J., Hildick-Smith, D., Colombo, A., Stanković, G., Iñiguez, A., Schultz, C., Kornowski, R., Ong, P. J. L., Alasnag, M., Rodriguez, A. E., Moschovitis, A., Laanmets, P., Donahue, M., Leonardi, S., & Smits, P. C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-10-28
- Volume
- 385
- Issue
- 18
- Pages
- 1643-1655
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3193614870
- Cited by
- 593
- References
- 17
- FWCI
- 57.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. https://app.cochat.ai/papers/10.1056/nejmoa2108749
- The paper
- Valgimigli, M., Frigoli, E., Heg, D., Tijssen, J., Jüni, P., Vranckx, P., Ozaki, Y., Morice, M.-C., Chevalier, B., Onuma, Y., Windecker, S., Tonino, P. A. L., Roffi, M., Lesiak, M., Mahfoud, F., Bartunek, J., Hildick-Smith, D., Colombo, A., Stanković, G., . . . Smits, P. C. (2021). Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2108749
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.